Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been implicated in polyubiquitin-mediated IL-1R/TLR signaling through activation of IκB kinase (IKK) to regulate the NF-κB and JNK signaling pathways. Here, TRAF6 protein was determined to be...
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M. Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez, Kyle Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R Berenson Haematologica...
There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study involving 264 individuals. Participants all had multiple myeloma with an initial visit occurring between 2004 and 2014. They had treatment at a clinic that...
Ariana Berenson Suzie Vardanyan Michael David James Wang Nika Manik Harutyunyan Jillian Gottlieb Ran Halleluyan Tanya M. Spektor Kyle A. Udd Shahrooz Eshaghian Youram Nassir Benjamin Eades Regina Swift James R. Berenson Abstract New classes of drugs including the...
Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S. Wang, Haiming Chen and James R. Berenson DOI: 10.1158/1078-0432.CCR-15-2224 Published July 2016 Abstract Purpose: Reduced...
Abstract Multiple myeloma (MM) is characterized by the enhanced production of the same monoclonal immunoglobulin (M-Ig or M protein). Techniques such as serum protein electrophoresis and nephelometry are routinely used to quantify levels of this protein in the serum...
Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-hour...
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal and Jesus G. Berdeja...
J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R A Swift3 and R A Vescio10 Department of Hematology/Oncology, Institute for Myeloma and Bone Cancer Research,...
James R Berenson, MD, Tanya M Spektor, PhD, and James Wang Institute for Myeloma & Bone Cancer Research; James R Berenson, MD, Inc; and ONCOtherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; jberenson@imbcr.org. Disclosures: Dr Berenson is...
Clinical Advances in Hematology & Oncology Authors: James R. Berenson, MD, Claudia Andreu-Vieyra, PhD, Sergio Giralt, MD...
Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Abstract Bendamustine, active in...
Leuk Res. 2012 Nov;36(11):1422-7. doi: 10.1016/j.leukres.2012.07.018. Epub 2012 Aug 17. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR. Abstract Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have...
Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA,...
Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. Abstract Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown...
